Targeting Different Transthyretin Binding Sites with Unusual Natural Compounds by Ortore, GABRIELLA MARIA PIA et al.
1 
 
Targeting different transthyretin binding sites  
with unusual natural compounds 
Dr. Gabriella Ortore*, Prof. Elisabetta Orlandini, Prof. Alessandra Braca, Dr. Lidia Ciccone, Prof. 
Armando Rossello, Prof. Adriano Martinelli, Dr. Susanna Nencetti*  
 
Dr. G. Ortore*, Prof. E. Orlandini, Prof. A. Braca, Dr. L. Ciccone, Prof. A. Rossello, Prof. A. 
Martinelli, Dr. S. Nencetti*  
Dipartimento di Farmacia  
Università di Pisa, V. Bonanno 6, 56126 Pisa 
E-mail: gabriella.ortore@unipi.it 
       susanna.nencetti@unipi.it 
   
Abstract 
Some nutraceuticals, such as flavonoids and natural poliphenols, have recently been investigated as 
modulators of the self-assembly process of transthyretin (TTR), but they suffer from generally limited 
bioavailability. To discover new innovative and more bioavailable natural compounds able to inhibit 
the TTR amyloids, the TTR crystallographic structure through a docking study was explored. The 
computational strategy was projected ad-hoc to inspect the possible relationship between binding site 
location and modulation of the assembly process: the interaction with the until now unexplored 
Epigallocatechin gallate (EGCG) sites and with the Thyroxine (T4) pocket were simultaneously 
analyzed. All the compounds studied seem to prefer the traditional T4 binding site, but some 
interesting results emerged from the screening of an in-house database, used for validating the 
computational protocol, and of the “Herbal Ingredients’ Targets” (HIT) catalogue available on the 
ZINC database. 
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Introduction 
Amyloidosis is a group of diseases sharing common pathogenic mechanisms, depending on the 
deposition of characteristic rigid fibrillar material (amyloids) in various organs and tissues. As these 
deposits build up, they begin to damage the structure and affect organ function. Systemic amyloidosis 
has been classified into three very different major types: primary (AL), caused by the accumulation of 
monoclonal immunoglobulin light chains as amyloid fibrils; secondary (AA), associated with chronic 
inflammatory diseases (e.g. rheumatoid arthritis); TTR amyloidosis (ATTR), non-hereditary due to 
fibrilization  of wild-type TTR and hereditary, due to a mutation in the gene encoding the plasma TTR 
protein. [1] 
TTR is a homo-tetrameric protein, made up of four 127-aminoacid subunits rich in β-sheets, which is 
synthesized mainly in the liver and the choroid plexus of the brain, and is present both in human 
plasma and in cerebrospinal fluid (CSF). TTR is involved in the transport of thyroxine (T4) in CSF as 
well as being a carrier of T4 and retinol in plasma with the assistance of the retinol binding protein. 
TTR circulates normally as an innocuous soluble protein but in some individuals it polymerizes to 
form  amyloid fibrils, inducing many diseases [2,3] like senile systemic amyloidosis (SSA), familial 
amyloid polyneuropathies (FAP), familial amyloid cardiomyopathy (FAC) and central nervous system 
selective amyloidosis (CNSA). These pathologies induce severe, life-threatening conditions, which 
can produce lethal consequences. In 1996 it was observed that amyloid fibril formation is prevented 
by the T4 binding; [4] unfortunately hormonal activity of thyroxine or their analogues makes its 
application an undesirable therapy.  
The mechanism of TTR amyloid fibril formation is not completely clarified, but the amyloidogenic 
potential of the protein might be related to its extensive β-sheet structure. Several observations and 
studies [5] seem to indicate that the first step consists of a conformational change, which induces the 
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dissociation of the tetramer, followed by the formation of an intermediate monomer, that at the end 
leads to self-assembly into insoluble amyloids.  
In the last decade some authors [6-9] discovered that several structurally different families of small 
molecules stabilize the tetramer of TTR, and more than 200 crystal structures of TTR complexes with 
more than 100 different ligands were deposited on the PDB database. Among these molecules the 
most interesting include several nonsteroidal anti-inflammatory drugs (NSAIDs), estrogen analogues, 
natural products or synthetic carboxylates that inhibit the TTR fibril formation. All these compounds 
bind the T4 binding site, at the TTR dimers interface. Only one crystal structure, the one co-
crystallized in 2010 with epigallocathechine gallate (EGCG), highlighted a second bind site location. 
In spite of their potency against TTR amyloidosis, NSAIDs  and estrogens have significant undesired 
effects due to long–term administrations. Only two TTR tetramer stabilizers are, at present, available 
for TTR amyloidosis therapy: tafamidis and diflunisal. Tafamidis has been approved for the treatment 
of FAP in European countries and Japan. Although tafamidis binds the TTR tetramer more tightly, 
diflunisal overcomes weaker TTR binding coefficients with high serum drug concentrations. Gene 
therapies with antisense oligonucleotides and small interfering RNAs are promising strategies to block 
TTR synthesis and are currently in clinical trials. In addition, some alternative mechanisms of amyloid 
inhibition are under study. [10] Recently, a strategy was suggested thanks to the TauRX Therapeutics 
Ltd studies for the Rember® trials in Alzheimer's Disease: the acceleration of the transition from 
oligomers to fibrils, which are less toxic than oligomers and protofibrils. [11] A second alternative 
strategy is to disrupt the self-association process itself, modulating the assembly process into the 
formation of nontoxic structures; the first evidence of this additional mechanism in TTR inhibition 
was referred to epigallocatechin. [12] Some authors [13] suggest that there could be a correlation 
between the different binding sites of EGCG in TTR and its alternative mechanism of fibrils 
inhibition. The alternative binding sites might be involved in the oligomerization of TTR tetramers, 
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leading to the formation of nontoxic, off-pathway aggregates. In addition to EGCG, some 
nutraceuticals such as flavonoids, natural poliphenols and caffeic acid, can modulate the self-assembly 
process, [10,14] but suffer from generally limited bioavailability. To discover new innovative and more 
bioavailable natural compounds able to inhibit the TTR amyloids, a computational study using the 
TTR three-dimensional structure was performed. Given the possible relationship between the binding 
site location and modulation of the assembly process, the interaction with the until now unexplored 
EGCG sites and with the T4 pocket was explored, simultaneously. All the potential ligands here 
studied seem to prefer the traditional T4 binding site, but some interesting results due to the variety 
and novelty of the given natural scaffolds emerged from the screening of an in-house database, used 
for validating the computational protocol, and of the “Herbal Ingredients’ Targets” (HIT) catalogue 
available on the ZINC database. [15] 
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Results 
Docking 
The small in house database of hydroxylated natural compounds reported in Chart 1 was added to the 
HIT database in order to explore the TTR binding sites. 
The docking results provide two different kinds of information about the interactions with TTR of the 
natural compounds here studied. Firstly, the disposition of the potential new inhibitors in the protein, 
targeting different binding sites: the traditional T4 pocket and the new EGCG sites (Figure 1).  
The blind docking procedure allowed us to explore the whole protein in a range of 30 Å from Ser23, a 
residue rather central within the known binding sites. The preferred docking position for all 
compounds was automatically calculated as described in the Experimental Section, and the results are 
here summarized. Only 92 within the 802 HIT compounds lay outside the T4 binding pocket, and 
within them, from a graphical analysis, 23 lay in the primary EGCG binding site. Among them, none 
interacted as EGCG between two adjacent monomers, as reported in Figure 2a, with three “anchors” 
pointing to Asp18 (right), TyrD114 (up) and SerA85 (left).   
Some occupied the monomers’ interface but could not reach Asp18 and TyrD114 (Figure 2b); some 
reached both Asp18 and TyrD114, but exposed lipophilic groups towards Asp18 (Figure 2c); others 
left empty the Asp18 and SerA85 pockets, reaching TyrD114 through lipophilic or aromatic moieties 
(Figure 2d); and in some cases compounds lay on the surface of only one monomer, scarcely fitting 
both the up and down interfaces (Figure 2e). Only three compounds filled all the pockets (Figure 2f), 
but engaged weaker interactions with respect to EGCG. Also within the in-house database only 2 
compounds seemed to prefer the primary EGCG binding site, bilobetin 10 and isoginkgetin 11, 
without any interaction with TyrD114. Compound 10, through its distal hydroxyl group, interacted 
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with Asp18, but the whole molecule inserted itself in the same monomer, having only a phenol in 
common with EGCG disposition (Figure 3a). All the other compounds lay in the T4 binding pocket.  
As regards the efficacy of the disposition in each binding site, the docking results were analyzed in 
view of the interaction with key residues, as described in the Experimental Section. These compounds 
were further analyzed on the basis of their docking score; in Table 1 are reported the values relative to 
the in-house database.  
As reported in Figure 4, some compounds showed interesting interactions, in spite of their structural 
diversity with respect to the usual inhibitors.  
In Figure 4a are reported compounds which showed the classical docking pose of the flavones: the 
poses of 7,4'-dihydroxyflavone 6, 7 (ZINC03871576: apigenin), 8 (ZINC03869685: quercetin), 9 
(ZINC03874317: myricetin), 15 (liquiritigenin) and 16 (ZINC00156701: naringenin) were 
corroborated by a docking score higher than 22. Also the flavanols 12 (ZINC00119983: catechin) and 
14 (fisetidinol) allowed a good interaction with Lys15 and Ser117 (see Figure 4b), with scores lower 
than but comparable to the flavones ones, in spite of the lack of the carbonyl group. Different with 
regard to the scaffolds but similar for some pharmacophoric portions, alloperiplogenin 21 (Figure 4c) 
and pinoresinol 23 (Figure 4d) permitted polar interactions with Lys15 and Ser117, less directional 
with respect to flavones but compensated through good steric relations with the binding pocket, which 
incremented the docking score. The hinge structures of chlorogenic acid 17, neochlorogenic acid 18 
(Figure 4e) and 5-O-galloylquinic acid 19 (Figure 4f), were able to fit into the T4 binding pocket with 
lower docking scores, but higher significance because of their unusual scaffolds. In particular 
compound 19  seemed to interact strongly with Lys15 through its quinic acid, and with Ser117 thanks 
to its gallic moiety. More complex, and very uncommon as a potential fibrils inhibitor, was the iridoid 
24, 6-O-(p-hydroxybenzoyl)-6-epiaucubin (Figure 4g). It was very interesting for the presence of a 
glucose moiety, that is frequently related to a decrease of TTR fibrils inhibition due to the 
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correspondent aglycones; [21] furthermore, it was very remarkable that the sugar portion lay in the 
inner part of the T4 binding site, in contrast with the flavonoid glycosides present in the HIT database 
and docked in the same way (data not shown). The hydroxybenzoyl moiety of 24 bound both 
monomers through Lys15, and the glucose one via Ser117; however, also in this case, the docking 
scores were lower than the flavones ones. Unfortunately, the aglycone of compound 24 was not 
available for a comparison. The evaluation of the sugar moiety influence was possible for the two 
neolignans urolignoside 3 and glochidiobioside 4 of the in-house database (Figure 4h). Also in this 
case, the glucose of 4 entered into the inner part of the binding site interacting with Ser117, and its 
aglycone portion was superimposed on the docking pose of compound 3, occupying the region 
towards Lys15. The presence of glucose seemed to ameliorate the interaction with Ser117, but the 
docking scores were very similar, specifically compound 4 was slightly worse.  
A separate description was due to 25 (rosmarinic acid), present in the HIT database as 
ZINC00899870, and already known as an inhibitor of V30M mutant TTR fibril formation. [20] As 
reported in Figure 4i, the docking pose calculated in the wt-TTR (sky-blue) was very similar to the 
experimental one (green, from PDB complex of V30M-TTR/ROA, code 4PWI). The good interaction 
was supported through a very high docking score.  
Bilobetin 10, present in the HIT database as ZINC03979028, as already described preferred the EGCG 
binding site. But the score difference between the EGCG-pose and the T4-pose was less than 0.5. In 
Figure 3 a comparison between the two binding modes was reported. Although it had a good docking 
score, the fitting with the EGCG binding site was not superposed on the experimental one: it seemed 
to occupy a border region. So, the docking into the T4 binding site was also analyzed: compound 10 
inserted only the apigenine moiety into the pocket, slightly distorted by the bulky 8-subtitution which 
lay outside the pocket. 
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Virtual Screening 
The docking results were ranked as described in the Experimental Section. Few compounds seemed to 
prefer binding with the EGCG site, and none seemed to fit effectively this region. So, the Virtual 
Screening (VS) was performed targeting the T4 binding pocket. The 710 HIT compounds preferring 
the T4 binding site were ranked on the basis of the key interactions with Lys15 and Ser117. They 
included apigenin 7, quercetin 8, myricetin 9, catechin 12, naringenin 16 and rosmarinic acid 25, 
available also in the in house database, and our compounds 1-6, 10-11, 13-15, 17-24. Bilobetin 10 was 
included despite its best score in EGCG because of its doubting behaviour. This enriched database 
included 14 actives and 5 inactives (see experimental section for details). Among the HIT compounds, 
293 interacted with both the lysines A15 and C15, and only a set of 119 compounds with at least one 
serine 117. All the in house compounds engaged interactions with the key residues. The 138 total 
surviving compounds were ranked on the basis of the docking score, and only scores higher than 20 
were accepted. In spite of the claimed imperfections and approximations of the scoring functions, [22] 
the use of the docking scores together with other computational methods, as in this case the 
interactions with key residues, allows good results in the structure-based design. [23] The ROC curve 
(Figure 5) shows that all the actives survived filtering and only 1 inactive compound was able to pass 
with the 88 hit compounds. In this VS, Recall was = 1, Precision = 0.93 and EF = 8.74; all these 
values indicated a good predictivity.  
For clarity, a schematic representation of the VS is reported in Figure 6. The surviving in-house 
database compounds are ranked in Table 2. Among these 15 compounds, 6 were already known as 
TTR fibril inhibitors. Their potency was not comparable because of the different methods for testing 
the effect on amyloid production. In some cases, such as for rosmarinic acid, the biological test was 
not performed on the wt-TTR. Within the 9 new potential inhibitors, some compounds were selected 
to test their ability to inhibit the fibril formation through a turbidimetric assay. The criterion used for 
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the selection was novelty in the molecule structure, thus liquiritigenin 15 was discarded for its 
similarity to the known naringenin. Between the enantiomers periplogenin 20 and alloperiplogenin 21 
was selected the best scored 21 and, between 12 and 14, the catechin 12. Furthermore, pinoresinol 23, 
compounds 3 and 4, very interesting for a comparison between an aglycone and its glycoside, and 
bilobetin 10, with its ambiguous and intriguing localization in the protein, were designated for the 
turbidimetric test. Rosmarinic acid 25, very good for interactions and docking score, was also tested to 
confirm its activity in non-amyloidogenic TTR. 
In spite of the lower docking scores, also compounds 19 and 24, for their structure novelty and 
significance of their docking pose, were selected for testing. 
 
Biological assay 
The natural compounds selected from the small in house library were tested for the inhibition of TTR 
fibril formation in an acid mediated turbidimetric assay. Figure 7 shows the percentage of TTR fibril 
formation (FF) evaluated by a doublet concentration of selected natural compounds to determine their 
potential as TTR fibril formation inhibitors. The concentration used in the tests (7.2 µM) represents 
twice the TTR concentration in plasma (3.6 µM). Diflunisal (9% FF) was used as the reference drug 
(positive control) while quercetin (11%), a known TTR inhibitor, as the reference natural compound. 
TTR without inhibitor under acid conditions (pH 4.2) was used as a negative control to determine the 
100% FF mark. [17] 
Analysis of the turbidimetric assay-results indicates that all the tested natural compounds were able to 
inhibit the fibrillogenesis with a percentage of fibril formation ranging from 15% to 73%; in 
particular, compound 25 with only 15% of fibril formation is the best inhibitor. The other natural 
compounds, 3, 4, 10, 12, 19, 21 and 23, showed a similar trend with an inhibitory activity around a 
value of 50% FF.   
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Discussion 
The possible role of natural compounds in the TTR amyloidoses is investigated by many research 
groups in view of their ability to impair TTR aggregation through different modes of action. Different 
compounds could suppress TTR tetramer dissociation, promote TTR oligomerization into small ‘‘off-
pathway’’ nontoxic aggregates, or reduce the amount of TTR aggregation. [19] In this context, we 
theoretically explored the wt-TTR structure to test novel natural potential inhibitors, targeting different 
sites of interaction and, therefore, presumable different modes of action. The docking procedure here 
described allowed us to discriminate which is the preferred site of interaction, for 820 natural 
compounds, in a range of 30 Å from a strategic centre of all the possible reported TTR binding sites. 
The searching of docking sites alternative to the T4 ones was successful only for 92 compounds, 
mostly concentrated near the primary EGCG site. Considering that this site lies on the surface of the 
protein, allowing a high level of freedom in the docking disposition, only 23 compounds fit into the 
RX ligand region and only three of them interact with the three EGCG “anchors”. However, it is 
interesting to highlight that compounds such as podophyllotoxin ZINC01532024, ginkgolides 
(ZINC04245650, ZINC08552016, ZINC08552017, ZINC95098816, ZINC95098818, ZINC95098819, 
ZINC95098830) and schisandrin ZINC02000967 (see Figure 2), are known or under study as 
protectors against Aβ toxicity. [24-27] Further studies are needed to examine in depth the role of 
ZINC05369365 analogues, and some assays are already in progress.  
The ambiguous bilobetin 10, which slightly prefers an alternative docking on the TTR surface 
interacting with Asp18, but with a comparable score interacts in the T4 pocket,  allowed the reduction 
of the fibril formation to about 50%. For this compound, the mechanism of inhibition could be not 
clear, given that the preferred binding site is unclear and the turbidimetric test could not give 
information about the inhibition process.  
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The docking results revealed, indeed, that the preferred binding site for the about 730 virtual screened 
compounds was the T4 pocket. This is compatible with the crystallographic trend: within the about 
120 ligands co-crystallized with TTR, only one (EGCG) shows a binding site different from the T4 
ones. The results will be discussed from two different points of view: the efficacy of the 
computational procedure and its effect on the compounds available in the in-house database. 
The VS was structured for emphasizing the role of the key interactions in the inhibitory activity. This 
is not a really essential requirement, because many active compounds have not polar interactions with 
Lys15 or Ser117 but, in particular within the natural molecules, all the compounds engaging hydrogen 
bonds with these residues show a strong reduction in TTR fibril formation (see Figure 8).  
We can consider this choice a good method for VS if the survived compounds enclose the known 
actives and discard the inactives. In our case, the HIT database comprises 14 actives and 5 inactives; 
our VS yields 88 compounds (15 of them available in the in-house database), which included the 
entire set of active compounds and only one inactive. In this context, we have to specify that genistin, 
and also the luteolin 7-glycosides, pass the screening, too late in the ROC curve. Unfortunately, this is 
an inescapable limit, due to the real evidence that flavonoid derivatives as glucuronides, considered 
mimics of glycosides, can bind effectively TTR without preventing the toxic response. [21] The 
crystallographic structure of some glucuronides [28] showed a good fit of these derivatives with the T4 
binding site, inserting the flavonoid into the pocket and placing the sugar outer, near Lys15, exactly as 
calculated by GOLD for the HIT analogues. Despite the crystallographic binding, they did not 
significantly compete with radiolabeled T4-TTR, [28] and had no effect on TTR toxicity. [21]  
Indeed, the VS protocol was able to discriminate known inhibitors and to reject the inactives, with the 
exception of the flavonoid glycosides which are not compatible with this method. This is validated by 
good enrichment factor values, and encourage us to further study the 15 hits available in our in-house 
database. Among them, 7,4'-dihydroxyflavone 6, apigenin 7, naringenin 16 and myricetin 9 have been 
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reported by many authors, and their activity on TTR fibril formation was already detected in wt-TTR 
by turbidity measurements. [16-17,28] In contrast, rosmarinic acid 25 has been firstly reported as not 
stabilizing TTR in whole plasma and not competing with [125I]T4 for its binding to TTR; [19] later it 
has been reported as a potent inhibitor of acid-mediated aggregation on the amyloidogenic variant 
V30M-TTR. [20] There was no evidence of wt-TTR fibril inhibition: our test verified the high activity 
of rosmarinic acid reducing the wt-TTR fibril formation to 15%. Furthermore, the docking pose 
suggested by GOLD was superimposed on the experimental one, validating the calculations both from 
a structural and activity perspective. 
As regards catechin 12, no data were available about its activity on TTR untill August 2015; in our 
turbidimetric test catechin allowed a fibril formation inhibition higher that 50%, coherently with the 
immunodetection of TTR aggregates published on L55P variant during the course of this study. [18]  
Also alloperiplogenin 21 and pinoresinol 23 halves the TTR fibril formation, very similar to catechin 
for their docking pose and score. The only steroid analogue already known as a TTR ligand was 16α-
Br-estradiol (4PM1 PDB code); [29] compound 21, having several hydroxyl groups and an ,-
unsaturated lactone ring, docked in a reversed pose in the T4 binding site and seems to slightly better 
inhibit TTR fibril formation. Pinoresinol 23 was the first lignan tested as TTR fibril formation 
inhibitor, but the lignan benign functions, such as their antioxidant activity and oestrogenic functions, 
as well as the protection against certain chronic diseases, are known. [30] Lignans are found in a wide 
range of food such as fruits, vegetables, flaxseed and beverages such as coffee, tea and wine. Less 
common, urolignoside 3 and its glucoside glochidiobioside 4 are very interesting, also for comparing 
the effect of the sugar on the aglycone activity. All the cases already reported in literature have shown 
a loss of TTR fibril inhibition with the insertion of glucose on flavonoids. [21,31] Their crystallographic 
structures show the insertion of flavonoid into the T4 pocket, positioning the sugar outside, towards 
and over Lys15. [21] In our docking, the glucose moiety of 4 interacted with Ser117 in the inner part of 
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the T4 pocket; the inhibition of TTR fibrils was maintained also transient from aglycone 3 to 
glucoside 4. This is the first active glycoside in TTR amyloid inhibition. To further analyze the sugar 
effect, also 6-O-(p-hydroxybenzoyl)-6-epiaucubin 24, whose docking seemed to engage good 
interactions with key residues despite the low score, being tested. The inhibitory activity was lesser, 
confirming the score significance in the filtering process of our VS. Finally, 5-O-galloylquinic acid 
19, ranked under the VS threshold, was tested as a sample of the quinic derivatives set (17-19), all 
interesting and pharmacophorically related to the oleuropein aglycone very recently reported as an 
inhibitor of TTR amyloid aggregate cytotoxicity [32]. The gallate 19 reduces the TTR fibril formation 
to 50%, and could be considered a false negative.  
All the compounds selected through this VS, indeed,  show they inhibit the deposit of TTR fibrils. The 
potency of new scaffolded inhibitors was not comparable with the flavonoids one, but it is an excellent 
starting point for lead optimization. Furthermore, the docking orientations reproduce the available 
crystallographic poses and give further information or suggestions about new possible binding modes 
of innovative scaffolds. 
 
Conclusions 
Starting from the recent results about some nutraceuticals able to modulate the self-assembly process 
in amyloidosis, the wt-TTR structure to search for novel natural potential inhibitors within three-
dimensional databases was studied through a computational approach. We targeted, through a focused 
procedure, different TTR binding sites, with the aim of presumably exploring alternative modes of 
action suggested by different behaviours of some natural compounds, in inhibiting the TTR amyloids. 
[10,19] The screening of innovative, different scaffolded compounds, could suggest novel and more 
bioavailable natural compounds as TTR fibril formation inhibitors. The computational procedure was 
validated through a VS, with good values of enrichment factors. Also the docking poses calculated for 
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some HIT database compounds, [15]  already co-crystallized into TTR, were in agreement with the 
experimental ones. A preliminary test for corroborating our VS was performed on the hit compounds; 
the turbidimetric results confirm the predictivity of our theoretical study, showing a noticeable 
inhibitory activity on the fibril formation for all the tested compounds. The structural diversity of the 
natural compounds here described opens a new perspective in the discovery of nutraceuticals, both in 
the lead optimization and in the further exploration of their biological role in TTR amyloidosis. 
 
Experimental Section 
Chemistry 
Compounds 4, 10, [33] 12, [34] 19, [35] 22, [36] 24 [37] and 25 [38] were isolated from different plant 
extracts, as previously reported. Quercetin 8 was obtained from Sigma-Aldrich. Compounds 3 and 23 
were purified from chloroform extract of Periploca graeca L. stems as following: the CHCl3 extract 
was purified by flash silica gel column chromatography as previously reported; [36] fraction 5 was 
purified by RP-HPLC on a C18 -Bondapak column (30 cm x 7.8 mm, flow rate 2.0 mL min-1) using 
MeOH-H2O 3:2 to yield pure compounds 3 and 23. 
Docking 
Automated docking into TTR of the HIT database’s ligands, [15] enriched with 18 compounds not 
enclosed in the HIT database but belonging to an in-house natural database, reported in Chart 1, was 
carried out by means of the GOLD 5.1 program. [39] The 18 ligands were built using the Maestro 
program, [40]  and subjected to a Conformational Search (CS) of 1000 steps in an implicit water 
solvation model using the Macromodel program. [41]  The Monte Carlo algorithm was used with the 
MMFFs forcefield, performing 100 step for rotatable bond with an energy window of 5 Kcal/mol, and 
eliminating the redundant conformers within a 0,5 Å of cutoff. An automatic setup of the torsion 
sampling options was performed during the calculation. The ligands were then minimized using the 
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Conjugated Gradient method to a convergence value of 0.05 kcal/Å∙mol, using the same forcefield and 
parameters as for the CS.  
The crystal structure of TTR was selected through a cross-docking that will be described in detail 
elsewhere, as the structure capable of better reproducing the co-crystal poses of wild-type TTR ligands 
deposited in Protein Data Bank (PDB). The region of interest of this complex, the 1Y1D PDB coded, 
[42] was defined in three different ways for three different and parallel docking procedures: a) for 
detecting the traditional T4 binding pocket, b) for exploring the EGCG one’s, and c) for extending the 
docking region over both the binding sites. In the a) case the pocket was defined within 10 Å from the 
1Y1D ligand iododiflunisal, allowing the flexibility of Ser117; in b) the EGCG coordinates were 
derived through the superposition of the 3NG5 coded crystal structure (EGCG-TTR complex) [43]  on 
the 1Y1D ones, and the binding site was defined within 10 Å from the translated EGCG. The Arg21 
side chain was allowed to adopt both the conformations of 1Y1D and 3NG5 crystal structures during 
the docking, using the EXTRA PARAMETER option of GOLD. Finally, in the c) procedure the 
binding site definition was independent from the ligands: it contains all the residues within 30 Å from 
the C alpha of the residue Ser23. Also in this case the Arg21 side chain was allowed to adopt both the 
conformations of 1Y1D and 3NG5 crystal structures during the docking. This protocol allows us to 
perform a blind docking considering all the cavities of the protein, using as a center of the docking 
cavity a point in the middle between the T4 and EGCG binding sites. Thus, the docking is performed 
simultaneously in all the known TTR binding sites. The ‘allow early termination’ command was 
deactivated in all a), b) and c) protocols. All the ligands were submitted to 40 Genetic Algorithm runs 
using the Chemscore fitness function, resulted the best fitness function in the previous cross-docking 
study, and clustering the output orientations on the basis of a RMSD distance of 1.5 Å. The default 
GOLD parameters were used for all the variables, except for the side chains rotamers. The top scored 
docking pose for each ligand was then used for further studies.  
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Analysis of the docking results and ranking of compounds 
The graphical analysis of the docking results was performed by Chimera. [44] They were analyzed from 
two points of view: the binding site localization (T4 and EGCG binding sites) and the docking 
goodness in terms of scores and interactions with the key residues of each binding site. The RMSD 
between the best docking pose produced by blind docking (bd-pose) and the best pose resulting from 
the docking in the T4 pocket (T4-pose) or in EGCG binding site (EGCG-pose) were evaluated through 
the rms analysis tool in the GOLD utilities. From a preliminary sample analysis was defined a 
threshold of RMSD between bd/T4-pose values lower than 12Å, which characterized the bd-poses 
inside the T4 binding site, and lower than 14Å for the RMSD between bd/EGCG-pose, which is 
typical for bd-poses preferring the EGCG binding site. In addition to the binding site localization, the 
interaction with both the lysines 15 and almost one of the serines 117 of the T4 binding site, and 
Asp18 or TyrD114 of EGCG binding site, were investigated. The hydrogen bonds calculation was 
performed using Chimera, and the results were elaborated through Excel, ranking compounds firstly 
on the basis of the presence of these interactions. Compounds engaging h-bonds with the key residues 
were further ranked on the basis of their docking score. 
Virtual Screening of HIT + inhouse database 
The HIT database was analyzed to check known actives as TTR fibrils inhibitors within the 802 
compounds. In view of the available data, some EC50 or turbidimetric results are known for 14 actives 
( 7,4'-dihydroxyflavone, myricetin, [16] catechin, gallic acid, epigallocatechin, epigallocatechin gallate, 
[18] curcumin, [45] genistein, daidzein, apigenin [28-31], luteolin [21] and rosmarinic acid [19] ) and 5 
inactives (caffeic acid, [20] estriol, genistin, [31] luteolin 7-O-galactoside, [21] mangiferin [46]). Thus, it is 
possible to virtual screen the database validating the calculation through the enrichment factor method. 
The threshold value for selecting the possible active compounds was defined analyzing the rate of 
actives and inactives in the ROC curve (Figure 5): a score value higher than 20 allowed to filter all the 
17 
 
actives and only 1 inactive compound. The VS results were evaluated using Recall, Precision and 
Enrichment. The Recall value for positives describes the ratio of correctly classified members of a 
data set, and is defined by the equation Recall = tp/(tp+fn), where tp is the number of active 
compounds not rejected (true positives) and fn is the number of active compounds rejected during the 
VS filtering (false negatives). The Precision gives the percentage of observed positives that are 
correctly predicted, and is defined by the equation Precision = tp/(tp+fp), where fp is the number of 
inactive compounds not rejected (false positives). The Enrichment Factor (EF) measures the 
enrichment of the method compared with random selection, and is defined by equation EF = 
Precision*NCtot/NC, where NCtot is the total number of molecules of the database (NCtot=802 
HIT+18 in-house) and NC is the total number of compounds obtained at the end of the VS protocol 
(88). Among the in-house database compounds showing a docking score higher than 20, therefore 
enclosed within the hits of the VS, were selected some structures to test, favouring the aglycones and 
maximizing the structural variability.  
Turbidimetric assay 
Wild-type TTR fibrillogenesis was evaluated in vitro by turbidimetric UV-vis assay at moderately 
acid pH (4.2). To ensure that the turbidity depended of TTR amyloid fibrils, the absence of absorbance 
at 400 nm was checked before assaying. 7.2 μM wt-TTR was preincubated (30 min) at neutral pH (10 
mM phosphate buffer, 100 mM KCl, 1.7 mM EDTA, pH 7.6) with 2 molar equivalents of natural 
compounds dissolved in DMSO, or DMSO and 2 molar equivalents of diflunisal for negative and 
positive controls, respectively. 200 mM acetate buffer, 100 mM KCl and 1.7 mM EDTA, was added 
to yield final pH 4.2. The microplate wells was then incubated (72h) at 37 °C to promote the 
fibrillogenesis. The percentage of fibril formation was determined by observing the increase in 
turbidity at 400 or 450 nm (for compound 8) in the absence and in the presence of inhibitors. 
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Chart 1: Natural compounds of our in-house database 
 
 
1: R = β-Glc; R1 = H 
2: R = H; R1 = β-Glc 
 
 
 
 
3: R = H 
4: R = β-Glc 
 
 
5: R = β-Glc 
 
 
6: R = H; R1 = H; R2 = H; R3 = H 
7: R = OH; R1 = H; R2 = H; R3 = H 
8: R = OH; R1 = OH; R2 = H; R3 =OH 
9: R = OH; R1 = OH; R2 = OH; R3 = OH 
 
 
10: R = H 
11: R = CH3 
 
 
12: R = OH; R1 = H 
13: R = OH; R1 = α-Rha 
14: R = H; R1 = H 
 
 
 
 
15: R = H 
16: R = OH 
 
17: R = ; R1 = H 
18: R = H; R1 =  
19: R =     ; R1 = H 
 
 
20: R = H;  R1 =  
21: R = H;  R1 =  
22: R = ;  R1 =  
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24: R = β-Glc 
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Table 1: Docking score of compounds 1-15 
Compound Docking Score 
1 14.7 
2 17.0 
3 21.7 
4 20.3 
5 14.7 
*6[a] 25.7 
*7( Apigenin) [b] 
ZINC03871576  
26.4 
*8 (Quercetin) [b] 
ZINC03869685  
23.6 
9 (Myricetin) [a] 
ZINC03874317  
23.2 
10 (Bilobetin) 
ZINC03979028 
19.6 
11 18.9 
*12 (Catechin) [c] 
ZINC00119983 
23.5 
13 13.7 
14 (Fisetidinol) 23.4 
15 (Liquiritigenin) 24.9 
*16 (Naringenin) [b] 
ZINC00156701 
23.5 
17 11.8 
18 13.8 
19 12.7 
20 23.8 
21 26.3 
22 19.2 
23 (Pinoresinol) 23.5 
24 9.5 
*25 (Rosmarinic Acid) [d,e] 
ZINC00899870  
25.2 
*Compounds already known as TTR fibrils inhibitors. [a]: Ref. [16]; [b]: Ref. [17]; [c]: Ref. [18]; [d]: Ref. [19]; [e]: Ref. 
[20] 
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Table 2 : Top scored in-house compounds ranking   
Compounds  
*7 (Apigenin) [a] 
21 
*6 [b] 
*25 (Rosmarinic Acid) 
[c,d] 
15 (Liquiritigenin) 
20 
*8 (Quercetin) [a] 
*12 (Catechin) [e] 
*16 (Naringenin) [a] 
23 (Pinoresinol) 
14 (Fisetidinol) 
*9 (Myricetin) [b] 
3 
4 
10 (Bilobetin) 
*Compounds already known as TTR fibrils inhibitors. [a]: Ref. [17]; [b]: Ref. [16]; [c]: Ref. [19]; [d]: Ref. [20]; 
 [e]: Ref. [18] 
 
 
Figure 1: TTR structure highlighting the traditional T4 pocket and the new EGCG sites. In magenta, 
the regions detected by GOLD for blind docking 
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Figure 2: Docking poses of the HIT compounds preferring the EGCG binding site, compared to the 
EGCG RX pose (a). Docking of ZINC01532024, ZINC04245650, ZINC08552016, ZINC13816216, 
ZINC31156201, ZINC95098816, ZINC950988168, ZINC95098819 (b); docking of ZINC02000967, 
ZINC43450320, ZINC95098766 (c); docking of ZINC30726694, ZINC95098792, ZINC95098793 
(d); docking of ZINC05369365, ZINC05369366, ZINC05369367 (e). 
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Figure 3: (a) Docking of 10 (purple) into EGCG binding site, compared with the experimental EGCG 
pose (cyan); (b) docking of 10 into the T4 binding pocket. 
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Figure 4: Docking of some in-house compounds in the T4 binding site: a) 6 (gold), 7 (magenta), 8 
(yellow), 9 (green), 15 (blue) and 16 (violet); b) 12 (grey) and 14 (violet); c) 21; d) 23; e) 17 (magenta) 
and 18 (green); f) 19; g) 24; h) 3 (gold) and 4 (green); i) 25 (blue sky) compared to the experimental 
one (green). 
 
 
 
 
27 
 
Figure 5: ROC curve of the VS. Serie 1: actives; serie 2: inactives. Yellow marked the in house 
database compounds. 
 
 
Figure 6: Scheme of our VS workflow 
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Figure 7: In vitro acid-mediated wt-TTR (7.2 µM) percentage of fibril formation in presence of the hit 
compounds. For each compound, the formation is reported as the mean±5 (standard error), from three 
independent determinations. 
 
 
Figure 8: Superimposition of 4WO0, 1TT6, 3FGU, 4WNJ and 1DVS crystallographic structures, 
showing the key interactions of apigenine (green), diethylstilbestrol (cyan), genisteine (pink), 
quercetine (puple) and resveratrol (gold). 
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TOC: Looking for a help from the plant kingdom for transthyretin amyloidosis by exploring different 
TTR binding sites through an in-house library of natural compounds 
 
